thiotepa has been researched along with Neuroectodermal Tumors, Primitive, Peripheral in 3 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
Neuroectodermal Tumors, Primitive, Peripheral: A group of highly cellular primitive round cell neoplasms which occur extracranially in soft tissue and bone and are derived from embryonal neural crest cells. These tumors occur primarily in children and adolescents and share a number of characteristics with EWING SARCOMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "From June 1997 to November 1999, 28 SRCT patients (median age, 26 years; 14 peripheral primitive neuroectodermal tumors [pPNETs], seven rhabdomyosarcomas [RMSs], and seven desmoplastic small round-cell tumors [DSRCTs]) received induction chemotherapy with ifosfamide, epirubicin, and vincristine followed by HD-CT." | 5.10 | High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study. ( Alloisio, M; Balzarotti, M; Bertuzzi, A; Castagna, L; Compasso, S; Nozza, A; Quagliuolo, V; Santoro, A; Siracusano, L; Soto Parra, H, 2002) |
| "ThioTEPA was administered intravenously every three weeks, at a dose of 65 mg/m2." | 2.68 | A phase II study of thioTEPA in children with recurrent solid tumor malignancies: a Children's Cancer Group study. ( Balis, FM; Bleyer, WA; Broxson, E; Geyer, JR; Heideman, R; Krailo, MD; Poplack, D; Sato, JK, 1996) |
| " The optimal dosage and schedule was 40 mg kg-1 daily for 5 days." | 1.29 | Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. ( Ardouin, P; Bénard, J; Bissery, MC; Boland, I; Bressac-de-Paillerets, B; Gouyette, A; Gyergyay, F; Morizet, J; Terrier-Lacombe, MJ; Vassal, G; Vénuat, AM, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vassal, G | 1 |
| Terrier-Lacombe, MJ | 1 |
| Bissery, MC | 1 |
| Vénuat, AM | 1 |
| Gyergyay, F | 1 |
| Bénard, J | 1 |
| Morizet, J | 1 |
| Boland, I | 1 |
| Ardouin, P | 1 |
| Bressac-de-Paillerets, B | 1 |
| Gouyette, A | 1 |
| Geyer, JR | 1 |
| Balis, FM | 1 |
| Krailo, MD | 1 |
| Heideman, R | 1 |
| Broxson, E | 1 |
| Sato, JK | 1 |
| Poplack, D | 1 |
| Bleyer, WA | 1 |
| Bertuzzi, A | 1 |
| Castagna, L | 1 |
| Nozza, A | 1 |
| Quagliuolo, V | 1 |
| Siracusano, L | 1 |
| Balzarotti, M | 1 |
| Compasso, S | 1 |
| Alloisio, M | 1 |
| Soto Parra, H | 1 |
| Santoro, A | 1 |
2 trials available for thiotepa and Neuroectodermal Tumors, Primitive, Peripheral
| Article | Year |
|---|---|
A phase II study of thioTEPA in children with recurrent solid tumor malignancies: a Children's Cancer Group study.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Humans; Neoplasms; Neuroectode | 1996 |
High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cyclophos | 2002 |
1 other study available for thiotepa and Neuroectodermal Tumors, Primitive, Peripheral
| Article | Year |
|---|---|
Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line; Cisplati | 1996 |